Prosperity Wealth Management Inc. Buys Shares of 29,250 Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Prosperity Wealth Management Inc. bought a new stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 29,250 shares of the company’s stock, valued at approximately $86,000. Prosperity Wealth Management Inc. owned about 0.11% of Vistagen Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Virtu Financial LLC raised its position in Vistagen Therapeutics by 30.5% in the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after purchasing an additional 4,722 shares during the last quarter. R Squared Ltd bought a new position in Vistagen Therapeutics in the fourth quarter valued at about $25,000. Jane Street Group LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at about $59,000. HighTower Advisors LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at about $64,000. Finally, Valence8 US LP acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at about $103,000. 78.39% of the stock is currently owned by institutional investors.

Vistagen Therapeutics Trading Up 2.6 %

Shares of VTGN stock opened at $2.79 on Thursday. The stock has a market cap of $80.52 million, a price-to-earnings ratio of -1.89 and a beta of 0.62. The stock has a 50-day moving average of $2.87 and a 200-day moving average of $2.91. Vistagen Therapeutics, Inc. has a 1-year low of $2.22 and a 1-year high of $5.74.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02. The company had revenue of $230 billion during the quarter, compared to analysts’ expectations of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. Sell-side analysts forecast that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.